Search - tctmd.com

Displaying 1 - 20 of 23

Sort: Relevancy | Date

TCTMD’s Top 10 Most Popular Stories for December 2023

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for December 2023

December 28, 2023

AHA Selects 2023’s Leading Cardiovascular Research

News Daily News

AHA Selects 2023’s Leading Cardiovascular Research

December 22, 2023

Who Benefits Most From Semaglutide and How Long Will That Take?

News Daily News

Who Benefits Most From Semaglutide and How Long Will That Take?

December 19, 2023

Stopping Tirzepatide Leads to Rebound in Weight, Cardiometabolic Risk

News Daily News

Stopping Tirzepatide Leads to Rebound in Weight, Cardiometabolic Risk

December 12, 2023

Mortality Risk Varies Among Patients With Very High LDL Levels

News Daily News

Mortality Risk Varies Among Patients With Very High LDL Levels

Michael O'Riordan

November 17, 2023

Full SELECT Results Affirm CV Risk Reduction With Semaglutide in Nondiabetics

News Conference News AHA 2023

Full SELECT Results Affirm CV Risk Reduction With Semaglutide in Nondiabetics

November 11, 2023

FDA Grants Tirzepatide a New Indication for Obesity Management

News Daily News

FDA Grants Tirzepatide a New Indication for Obesity Management

November 08, 2023

Semaglutide Works Across LVEF Range: STEP-HFpEF Analysis

News Conference News HFSA 2023

Semaglutide Works Across LVEF Range: STEP-HFpEF Analysis

October 11, 2023

Major GI Events Rare but Real in Weight-Loss Patients on GLP-1 Drugs

News Daily News

Major GI Events Rare but Real in Weight-Loss Patients on GLP-1 Drugs

October 06, 2023

GLP-1 Meds Linked to 265 Reports to FDA of Suicidal Ideation: Reuters

News Daily News

GLP-1 Meds Linked to 265 Reports to FDA of Suicidal Ideation: Reuters

September 28, 2023

Lorundrostat, an Aldosterone Synthase Inhibitor, Passes Phase II Hurdle

News Daily News

Lorundrostat, an Aldosterone Synthase Inhibitor, Passes Phase II Hurdle

September 12, 2023

STEP-HFpEF: Semaglutide Cuts Weight and Symptoms, Boosts Function

News Conference News ESC 2023

STEP-HFpEF: Semaglutide Cuts Weight and Symptoms, Boosts Function

August 25, 2023

SELECT: Semaglutide Cuts CV Events in Adults With Overweight or Obesity

News Daily News

SELECT: Semaglutide Cuts CV Events in Adults With Overweight or Obesity

August 08, 2023

EMA Investigating Suicidal Thinking With GLP-1 Drugs for Weight Loss

News Daily News

EMA Investigating Suicidal Thinking With GLP-1 Drugs for Weight Loss

Michael O'Riordan

July 12, 2023

Acute MI Patients Without Standard CVD Risk Factors at Higher Risk of Death

News Daily News

Acute MI Patients Without Standard CVD Risk Factors at Higher Risk of Death

Michael O'Riordan

July 07, 2023

Oral, Daily Semaglutide Cuts Pounds in Nondiabetic Patients: OASIS 1

News Conference News ADA 2023

Oral, Daily Semaglutide Cuts Pounds in Nondiabetic Patients: OASIS 1

June 29, 2023

Dramatic Weight Loss, Cardiometabolic Improvement With Retatrutide

News Conference News ADA 2023

Dramatic Weight Loss, Cardiometabolic Improvement With Retatrutide

June 28, 2023

Skyrocketing Popularity Puts GLP-1 Agonists for Weight Loss on Cardiology’s Radar

News Features

Skyrocketing Popularity Puts GLP-1 Agonists for Weight Loss on Cardiology’s Radar

May 12, 2023

To Improve CV Care in US South Asians, Understand Unique ASCVD Risks: ACC

News Daily News

To Improve CV Care in US South Asians, Understand Unique ASCVD Risks: ACC

Yael L. Maxwell

April 12, 2023

Regaining Weight Won’t Erode CV Risk Factor Benefits Short Term

News Daily News

Regaining Weight Won’t Erode CV Risk Factor Benefits Short Term

March 31, 2023

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.